Prostate cancer · Oligorecurrent HSPC · MDT vs observation
ORIOLE
Does SABR reduce early progression compared with observation in recurrent HSPC with 1–3 metastases?
Randomized phase II; n=54. SABR vs observation.
Arms / design
Randomized phase II; n=54. SABR vs observation.
Outcome visualization · source-reported data
Progression at 6 months
PFS HR 0.30 (95% CI 0.11–0.81); p=0.002
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Progression occurred in 7/36 vs 11/18 patients (p=0.005); no grade ≥3 toxicity observed.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/32215577/
Primary source
undefined